JOHNSON & JOHNSON

JNJ

JOHNSON & JOHNSON

JNJ

Insider Sentiment (TTM):

Last Purchase:2025-11-26Last Sale:2026-06-11Shares Purchased (TTM):1,250Shares Sold (TTM):529,159

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:1,647,448,721Shares Outstanding:2,408,700,000Institutional Ownership Pct.:68.40%

Earnings Market Reaction:

Filing Date:2026-07-23Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Pharmaceutical Preparations

LLY ABBV MRK ABT PFE BMY

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Cash And Cash Equivalents At Carrying Value	20,422	21,688	19,709	18,231	18,577	38,474	24,105	19,980	24,878	25,473	21,859	19,728
Marketable Securities Current	336	363	393	331	303	307	417	317	597	745	1,068	3,783
Accounts Receivable Net Current	19,046	17,721	17,178	17,611	17,846	16,020	14,842	16,174	15,794	14,946	14,873	14,798
Inventory Net	15,144	14,583	14,191	14,146	13,412	12,659	12,444	12,603	12,169	11,383	11,181	11,198
Prepaid Expense And Other Assets Current	4,826	4,818	4,153	4,292	4,360	4,091	4,085	4,175	4,379	4,455	4,514	4,196
Assets Current	59,774	59,173	55,624	54,611	54,498	71,551	55,893	53,249	57,817	57,002	53,495	53,703
Assets Of Disposal Group Including Discontinued Op…	-	-	-	-	-	-	-	-	-	-	0	0
Property Plant And Equipment Gross	55,518	54,695	-	53,375	52,472	49,884	-	49,274	48,035	47,585	-	45,626
Accumulated Depreciation Depletion And Amortizatio…	-31,936	-31,425	-	-31,037	-30,523	-29,013	-	-28,795	-28,287	-27,953	-	-26,805
Property Plant And Equipment Net	23,582	23,270	23,169	22,338	21,949	20,871	20,518	20,479	19,748	19,632	19,898	18,821
Intangible Assets Net Excluding Goodwill	48,229	49,061	50,403	48,737	49,835	36,755	37,618	39,490	39,725	34,286	34,175	35,021
Goodwill	48,479	48,558	48,772	48,048	48,117	44,468	44,200	44,799	44,250	36,616	36,558	36,124
Deferred Income Tax Assets Net	6,728	6,727	6,874	6,666	6,801	8,492	10,461	9,349	9,004	10,305	9,279	9,259
Other Assets Noncurrent	14,269	14,105	14,368	12,416	12,189	11,534	11,414	10,921	10,544	14,125	14,153	13,133
Assets	201,061	200,894	199,210	192,816	193,389	193,671	180,104	178,287	181,088	171,966	167,558	166,061
Liabilities And Stockhold…
Disposal Group Including Discontinued Operation As…	-	-	-	-	-	-	-	-	-	-	0	0
Liabilities Current
Short Term Borrowings	11,692	17,460	8,495	6,387	11,526	13,897	5,983	4,462	9,855	8,550	3,451	3,870
Accounts Payable Current	9,223	10,460	11,991	9,625	9,464	9,545	10,311	8,954	8,848	8,174	9,632	8,355
Accrued Liabilities Current	9,464	7,399	8,594	7,601	7,404	7,913	8,549	11,450	10,539	10,323	10,212	10,101
Employee Related Liabilities Current	3,475	2,911	4,534	3,972	3,298	2,551	4,126	3,620	2,843	2,178	3,993	3,337
Accrued Income Taxes Current	1,051	1,087	1,388	1,928	1,665	4,217	3,772	4,834	4,309	3,318	2,993	2,899
Liabilities Current	54,895	57,716	54,126	50,869	54,180	56,903	50,321	51,759	53,933	48,725	46,282	44,370
Long Term Debt Noncurrent	37,344	37,527	39,438	39,408	39,235	38,355	30,651	31,289	31,636	25,082	25,881	26,051
Deferred Income Tax Liabilities Net	6,608	7,011	6,791	5,988	3,799	2,428	2,448	2,952	2,635	3,172	3,193	2,623
Liabilities Of Disposal Group Including Discontinu…	-	-	-	-	-	-	-	-	-	-	0	0
Employee Related Liabilities Current And Noncurren…	6,657	6,760	6,957	6,930	7,021	7,046	7,255	6,852	6,919	7,019	7,149	5,687
Accrued Income Taxes Noncurrent	485	486	486	418	418	395	390	354	341	2,881	2,881	2,540
Other Liabilities Noncurrent	10,101	10,208	9,868	9,926	10,263	10,435	17,549	14,923	14,086	15,067	13,398	13,562
Liabilities	116,090	119,708	117,666	113,539	114,916	115,562	108,614	108,129	109,550	101,946	98,784	94,833
Stockholders Equity
Liabilities Of Disposal Group Including Discontinu…	-	-	-	-	-	-	-	-	-	-	0	0
Preferred Stock Value	-	-	0	-	-	-	0	-	-	-	0	-
Common Stock Value	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120
Accumulated Other Comprehensive Income Loss Net Of…	-13,951	-14,831	-14,930	-15,237	-14,305	-11,740	-11,741	-12,522	-11,253	-10,768	-12,527	-8,780
Retained Earnings Accumulated Deficit	171,665	169,161	168,978	167,281	165,371	162,635	155,791	155,179	155,360	153,378	153,843	152,536
Treasury Stock Value	-	-	75,624	-	-	-	75,680	-	-	-	75,662	-
Treasury Stock Common Value	75,863	76,264	-	75,887	75,713	75,906	-	75,619	75,689	75,710	-	75,648
Stockholders Equity	84,971	81,186	81,544	79,277	78,473	78,109	71,490	70,158	71,538	70,020	68,774	71,228
Liabilities And Stockholders Equity	201,061	200,894	199,210	192,816	193,389	193,671	180,104	178,287	181,088	171,966	167,558	166,061
Assets Current
Allowance For Doubtful Accounts Receivable Current	171	174	183	176	185	170	167	153	161	162	166	160
Preferred Stock Shares Authorized	-	-	2	-	-	-	2	-	-	-	2	-
Common Stock Par Or Stated Value Per Share	1	1	1	1	1	1	1	1	1	1	1	1
Common Stock Shares Authorized	4,320	4,320	4,320	4,320	4,320	4,320	4,320	4,320	4,320	4,320	4,320	4,320
Common Stock Shares Issued	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120	3,120
Treasury Stock Common Shares	712	713	712	714	713	714	713	713	713	713	713	713

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	0.27%	7.15%	14.31%	-	-	-	-	-	-	-	-	-
2025	-2.61%	1.97%	1.84%	4.18%	5.78%	13.30%	1.55%	10.36%	6.61%	0.34%	1.44%	-5.17%
2024	-2.00%	-0.81%	3.15%	-0.16%	4.47%	1.91%	-7.15%	-10.89%	-13.66%	6.85%	-1.77%	0.08%
2023	-	-	-	-0.04%	-3.50%	-8.01%	2.88%	7.42%	12.42%	1.90%	-2.66%	-4.65%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	1.09	1.03	1.03	1.07	1.01	1.26	1.11	1.03	1.07	1.17	1.16	1.21
Quick Ratio	0.73	0.69	0.69	0.71	0.68	0.96	0.78	0.70	0.77	0.84	0.82	0.86
Working Capital	4.88B	1.46B	1.50B	3.74B	318.00M	14.65B	5.57B	1.49B	3.88B	8.28B	7.21B	9.33B
Leverage & Debt
Debt to Equity	1.37	1.47	1.44	1.43	1.46	1.48	1.52	1.54	1.53	1.46	1.44	1.33
Interest Coverage TTM	25.90	25.00	34.55	36.24	33.48	34.09	23.10	28.41	65.38	59.00	48.78	39.89
Debt Ratio	0.58	0.60	0.59	0.59	0.59	0.60	0.60	0.61	0.60	0.59	0.59	0.57
Efficiency & Turnover
Asset Turnover TTM	0.50	0.49	0.50	0.50	0.48	0.49	0.51	0.51	0.46	0.47	0.48	0.45
Days Sales Outstanding TTM	68.75	63.90	62.04	66.91	67.74	63.26	61.06	64.45	68.66	66.69	61.96	73.39
Receivables Turnover TTM	5.31	5.71	5.88	5.46	5.39	5.77	5.98	5.66	5.32	5.47	5.89	4.97
Per Share Metrics
Diluted EPS TTM	8.62	8.60	11.03	10.34	9.37	9.00	5.79	6.05	15.70	15.83	13.73	13.58
Free Cash Flow Per Share TTM	9.24	7.38	8.18	8.14	7.71	8.46	8.24	8.62	8.44	7.77	7.20	6.24
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	67.91%	67.82%	67.88%	68.08%	67.92%	68.30%	69.07%	69.05%	69.06%	69.20%	68.82%	70.30%
Operating Profit Margin TTM	25.73%	25.88%	34.59%	34.19%	30.18%	29.78%	18.79%	20.10%	22.53%	23.42%	17.69%	16.67%
Net Profit Margin TTM	21.48%	21.83%	28.46%	27.26%	25.00%	24.41%	15.84%	16.74%	43.91%	44.92%	41.28%	45.37%
Growth Metrics
Net Revenue Growth (1Y)	8.06%	7.87%	6.05%	5.08%	4.68%	4.30%	4.30%	14.92%	15.50%	10.57%	6.46%	-17.27%
Net Income Growth (1Y)	-7.17%	-3.53%	90.56%	71.06%	-40.39%	-43.32%	-59.99%	-57.59%	191.24%	202.39%	95.94%	80.74%
EPS Growth (1Y)	-7.21%	-3.59%	90.55%	70.99%	-40.38%	-43.29%	-57.89%	-55.55%	214.42%	227.16%	103.03%	88.26%
Valuation Metrics
P/E TTM	29.06	27.82	18.38	17.47	15.82	17.71	23.75	25.29	8.74	9.28	10.51	10.47
P/B TTM	7.20	7.21	6.04	5.54	4.57	4.94	4.67	5.29	4.65	5.10	5.37	5.09
P/S TTM	6.24	6.08	5.23	4.76	3.96	4.32	3.76	4.23	3.84	4.17	4.34	4.75
Market Cap	611.41B	585.42B	492.74B	438.86B	358.60B	386.17B	334.10B	371.39B	332.37B	357.05B	369.38B	362.61B
Enterprise Value	640.02B	618.71B	520.97B	466.42B	390.79B	399.95B	346.62B	387.16B	348.99B	365.21B	376.86B	372.80B
Calculated Values
Free Cash Flow TTM	22.24B	17.78B	19.70B	19.60B	18.55B	20.37B	19.84B	20.75B	20.30B	18.70B	18.25B	15.74B
Net Debt	28.61B	33.30B	28.22B	27.56B	32.18B	13.78B	12.53B	15.77B	16.61B	8.16B	7.47B	10.19B
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-11Sale

Owner: Wengel, Kathryn E

Title: EVP, Chief TO and Risk Officer

Shares: 10,000

Price/Share: $241.15

Value: $2,411,500.00

Shares Owned: 114,288

Relationship: Officer

Ownership: Direct

2026-02-27Sale

Owner: Decker, Robert J

Title: VP Corporate Controller

Shares: 4,075

Price/Share: $247.87

Value: $1,010,070.25

Shares Owned: 23,682

Relationship: Officer

Ownership: Direct

2026-02-20Sale

Owner: Schmid, Timothy

Title: EVP, WW Chair, MedTech

Shares: 1,322

Price/Share: $245.66

Value: $324,762.52

Shares Owned: 25,447

Relationship: Officer

Ownership: Direct

2026-02-18Sale

Owner: Schmid, Timothy

Title: EVP, WW Chair, MedTech

Shares: 22,623

Price/Share: $244.36

Value: $5,528,156.28

Shares Owned: 26,769

Relationship: Officer

Ownership: Direct

2026-02-17Sale

Owner: Broadhurst, Vanessa

Title: EVP, Global Corp Affairs

Shares: 6,197

Price/Share: $243.39

Value: $1,508,287.83

Shares Owned: 23,003

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-11	Wengel, Kathryn E	Officer	EVP, Chief TO and Risk Officer	Direct	Sale	10,000	241.15	$2,411,500.00	114,288	4
2026-02-27	Decker, Robert J	Officer	VP Corporate Controller	Direct	Sale	4,075	247.87	$1,010,070.25	23,682	4
2026-02-20	Schmid, Timothy	Officer	EVP, WW Chair, MedTech	Direct	Sale	1,322	245.66	$324,762.52	25,447	4
2026-02-18	Schmid, Timothy	Officer	EVP, WW Chair, MedTech	Direct	Sale	22,623	244.36	$5,528,156.28	26,769	4
2026-02-17	Broadhurst, Vanessa	Officer	EVP, Global Corp Affairs	Direct	Sale	6,197	243.39	$1,508,287.83	23,003	4
2026-02-17	Wolk, Joseph J	Officer	Exec VP, CFO	Direct	Sale	89,654	242.82	$21,769,784.28	14,000	4
2026-02-17	Reed, John C	Officer	EVP, Innovative Medicine, R&D	Direct	Sale	53,931	243.00	$13,105,233.00	10,658	4
2026-02-17	Swanson, James D.	Officer	EVP, CIO	Direct	Sale	20,521	242.70	$4,980,446.70	25,698	4
2026-01-26	Duato, Joaquin	Director,Officer	CEO and Chairman of the Board	Indirect	Sale	100,000	221.24	$22,124,000.00	30,852	4
2025-11-26	Morikis, John G	Director	-	Direct	Purchase	1,250	206.15	$257,687.50	1,849	4
2025-10-17	Reed, John C	Officer	EVP, Innovative Medicine, R&D	Direct	Sale	21,721	192.71	$4,185,853.91	10,658	4
2025-09-04	Taubert, Jennifer L	Officer	EVP, WWC. Innovative Medicine	Direct	Sale	56,471	177.81	$10,041,108.51	178,013	4
2025-08-22	Duato, Joaquin	Director,Officer	CEO and Chairman of the Board	Direct	Sale	125,824	179.21	$22,548,919.04	275,967	4
2025-08-15	Wolk, Joseph J	Officer	Exec VP, CFO	Direct	Sale	16,820	176.91	$2,975,626.20	14,000	4
2025-07-17	Reed, John C	Officer	EVP, Innovative Medicine, R&D	Direct	Sale	19,137	163.55	$3,129,856.35	10,658	4
2025-02-25	Decker, Robert J	Officer	VP Corporate Controller	Direct	Sale	6,999	165.88	$1,160,994.12	21,001	4
2025-02-18	Schmid, Timothy	Officer	EVP, WW Chair, MedTech	Direct	Sale	403	156.15	$62,928.45	15,098	4
2025-02-07	Wolk, Joseph J	Officer	Exec VP, CFO	Direct	Sale	13,015	153.89	$2,002,878.35	0	4
2024-12-12	Weinberger, Mark A	Director	-	Direct	Purchase	1,000	147.22	$147,220.00	1,000	4
2024-08-30	Decker, Robert J	Officer	VP Corporate Controller	Direct	Sale	5,635	165.06	$930,113.10	18,973	4
2024-04-30	Woods, Eugene A.	Director	-	Indirect	Purchase	100	145.53	$14,553.00	250	5
2024-03-13	Broadhurst, Vanessa	Officer	EVP, Global Corp Affairs	Direct	Sale	8,891	162.16	$1,441,764.56	15,043	4
2024-02-09	Taubert, Jennifer L	Officer	EVP, WW Chair, Pharmaceuticals	Direct	Sale	59,397	156.27	$9,281,969.19	141,416	4
2023-07-26	Hait, William	Officer	See Remarks	Direct	Sale	14,698	172.00	$2,528,056.00	87,747	4
2023-07-25	Fasolo, Peter	Officer	Exec VP, Chief HR Officer	Direct	Sale	20,000	170.32	$3,406,400.00	102,696	4
2023-06-12	Wengel, Kathryn E	Officer	EVP, Chief TO and Risk Officer	Direct	Sale	12,465	160.00	$1,994,400.00	65,934	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

68.40%

Inst. Shares: 1,647,448,721

Shares Outstanding: 2,408,700,000

2025-12-31

70.99%

Inst. Shares: 1,709,123,687

Shares Outstanding: 2,407,400,000

2025-09-30

69.36%

Inst. Shares: 1,670,350,092

Shares Outstanding: 2,408,300,000

2025-06-30

69.93%

Inst. Shares: 1,682,826,666

Shares Outstanding: 2,406,300,000

2025-03-31

68.19%

Inst. Shares: 1,641,469,156

Shares Outstanding: 2,407,200,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	1,647,448,721	2,408,700,000	68.40%
2025-12-31	1,709,123,687	2,407,400,000	70.99%
2025-09-30	1,670,350,092	2,408,300,000	69.36%
2025-06-30	1,682,826,666	2,406,300,000	69.93%
2025-03-31	1,641,469,156	2,407,200,000	68.19%
2024-12-31	1,651,150,824	2,407,300,000	68.59%
2024-09-30	1,597,135,958	2,407,200,000	66.35%
2024-06-30	1,604,018,676	2,406,800,000	66.65%
2024-03-31	1,533,354,323	2,408,200,000	63.67%
2023-12-31	1,550,531,860	2,533,500,000	61.20%
2023-09-30	1,482,920,457	2,522,900,000	58.78%
2023-06-30	1,593,115,745	2,598,400,000	61.31%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

JOHNSON & JOHNSON (JNJ) — SEC Financial Statements & Analysis

JOHNSON & JOHNSON (JNJ) is a pharmaceutical preparations company, incorporated in NJ. JOHNSON & JOHNSON trades on JNJ: NYSE as: JNJ. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), JOHNSON & JOHNSON reported a 8.06% year-over-year revenue growth, a Gross Profit Margin of 67.91% (TTM), a Debt-to-Equity ratio of 1.37x, a Price-to-Sales (P/S) ratio of 6.24x (TTM), a Price-to-Book (P/B) ratio of 7.2 (TTM), at a market cap of $611.41B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 8.06%
Gross Profit Margin TTM: 67.91%
Debt To Equity: 1.37x
P/S TTM: 6.24x
P/B TTM: 7.2
Market Cap: $611.41B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is JOHNSON & JOHNSON in?

JOHNSON & JOHNSON (JNJ) operates in the Pharmaceutical Preparations industry.

What is JNJ's market cap?

JOHNSON & JOHNSON (JNJ) has a market capitalization of $611.41B as of 2026-06-30.

What is JNJ's P/E ratio?

JOHNSON & JOHNSON (JNJ)'s trailing twelve month P/E ratio is 29.06x as of 2026-06-30.

What exchange does JNJ trade on?

JOHNSON & JOHNSON (JNJ) trades on the JNJ: NYSE.

Where is JOHNSON & JOHNSON incorporated?

JOHNSON & JOHNSON is incorporated in NJ.

JOHNSON & JOHNSON (JNJ) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.